Skip to content
BCI.INTEL
NLINKN1 Chip+PRIME.StudySYNCRStentrode+$200M.SeriesDPRECNLayer 7+FDA.BrkthruPARAMArgo+$20M.SeriesBBLKRKNeuroport+200.ImplantsEMTIVMN8+$45M.SeriesBKRNLFlux+Non-invasiveNRBLEHalo+Consumer.BCINEURONeuroPace+RNS.SystemCOGNICognixion+ALS.TrialFUND.YTD2026$2.8B.SectorTRIALSActive50+.ClinTrialsIMPLNTSHumans~100.Intracrtnl
Terminal/Device DB/RNS System (Responsive Neurostimulation)
ECoGPMA-approvedapproved

RNS System (Responsive Neurostimulation)

Implant Type
ECoG
Electrodes
4
Channels
4
FDA Status
PMA-approved
Clinical Stage
Post-market (FDA PMA approved November 2013)
Status
approved
About

The NeuroPace RNS System is the first FDA-approved closed-loop brain stimulation device, designed specifically for drug-resistant focal epilepsy. A neurostimulator the size of a matchbook is implanted in a cranial recess; up to two leads with strip or depth electrodes are placed at seizure foci. The device continuously monitors cortical EEG in real time, detects abnormal electrical patterns indicative of impending seizures, and automatically delivers brief counter-stimulation pulses without patient action. Long-term data from the RESPONSE trial shows a median 75% reduction in seizures at 9 years post-implant, with some patients achieving seizure freedom.

Target Conditions
drug-resistant focal epilepsy
Milestones
2004-01RESPONSE pivotal trial initiated
2013-11FDA PMA approval for drug-resistant focal epilepsy
2021-04IPO on Nasdaq (NPCE), raised $140M
2023-019-year RESPONSE follow-up: 75% median seizure reduction published
FDA Regulatory Pathway
No FDA Regulatory Status

This device does not have a current FDA designation. It may be a research tool, preclinical device, or consumer product not subject to FDA medical device regulation.

FDA Device Regulatory Guidance ↗
Other ECoG Devices